Although some benefits, such as reduced contrast-induced acute kidney injury, have been observed, current evidence does not fully support the use of SGLT2 inhibitors in ACS management, regardless of diabetes status [18]. This evidence concerns the gene SLC5A2 and acute kidney injury.